Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium sa-nv - clostridium haemolyticum toxoid >= 16,5 u/ml; tetanus toxoid >= 2,5 u/ml; clostridium septicum toxoid >= 3,6 u/ml; clostridium novyi toxoid >= 1,2 u/ml; clostridium perfringens type c (beta) toxoid >= 12,4 u/ml; clostridium perfringens type d (epsilon) toxoid >= 5,1 u/ml; clostridium perfringens type a toxoid >= 0,9 u/ml; clostridium perfringens type b toxoid >= 12,4 u/ml; clostridium chauvoei (inactivated) ; clostridium sordellii toxoïd >= 0,8 u/ml - suspension for injection - clostridium chauvoei-septicum; clostridium haemolyticum toxoid; clostridium novyi toxoid; clostridium perfringens; clostridium tetani toxoid; clostridium sordellii toxoid - clostridium - cattle; sheep

New Zealand - English - Ministry for Primary Industries

elanco new zealand - sodium selenate; clostridium chauvoei toxoid/cells; clostridium tetani toxoid; hydroxocobalamin; clostridium septicum toxoid; clostridium perfringens type d toxoid; clostridium novyi type b toxoid/cells - sodium selenate 6 g/litre; clostridium chauvoei toxoid/cells 0 vaccine; clostridium tetani toxoid 0 vaccine; hydroxocobalamin 1 g/litre; clostridium septicum toxoid 0 vaccine; clostridium perfringens type d toxoid 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine - parenteral nutrient/electrolyte

New Zealand - English - Ministry for Primary Industries

elanco new zealand - levamisole phosphate; clostridium chauvoei toxoid/cells; vitamin b12; clostridium tetani toxoid; clostridium septicum toxoid; clostridium novyi type b toxoid/cells; clostridium sordellii toxoid/cells; sodium selenate; clostridium perfringens type d toxoid - levamisole phosphate 220 g/litre; clostridium chauvoei toxoid/cells 0 vaccine; vitamin b12 1 g/litre; clostridium tetani toxoid 0 vaccine; clostridium septicum toxoid 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine; clostridium sordellii toxoid/cells 0 vaccine; sodium selenate 4.31 g/litre; clostridium perfringens type d toxoid 0 vaccine - endoparasiticide

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - clostridium perfringens, clostridium tetani - suspension for injection - inactivated bacterial vaccine - pigs, sheep

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - clostridium chauvoei, clostridium perfringens, clostridium septicum, clostridium tetani, mannheimia haemolytica, pasteurella trehalosi - solution for injection - inactivated bacterial vaccine - sheep

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - clostridium perfringens type d (epsilon) toxoid ; clostridium perfringens type c (beta) toxoid >= 18,2 iu/dose; clostridium perfringens type b toxoid >= 18,2 iu/dose; clostridium sordellii toxoïd >= 4,4 u/ml; clostridium perfringens type a (alfa) toxoid >= 0,5 u/ml; clostridium novyi toxoid >= 3,8 iu/ml; clostridium septicum toxoid >= 4,6 elisa u/dose; clostridium chauvoei (inactivated) ; clostridium haemolyticum toxoid >= 17,4 u/ml; tetanus toxoid >= 4,9 elisa u/dose - suspension for injection - clostridium haemolyticum toxoid; clostridium tetani toxoid; clostridium novyi toxoid; clostridium chauvoei; clostridium perfringens; clostridium sordellii toxoid - clostridium - cattle; sheep

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

idt biologika gmbh - clostridium perfringens type a/c, beta2 toxoid ; clostridium perfringens type a/c, alfa toxoid ; clostridium perfringens type a/c, beta1 toxoid - lyophilisate and solvent for suspension for injection - clostridium perfringens type a/c, alfa toxoid; clostridium perfringens type a/c, beta1 toxoid; clostridium perfringens type a/c, beta2 toxoid - clostridium - pig

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

idt biologika gmbh - clostridium perfringens type a/c, beta2 toxoid ; clostridium perfringens type a/c, alfa toxoid ; clostridium perfringens type a/c, beta1 toxoid - lyophilisate and solvent for suspension for injection - clostridium perfringens type a/c, alfa toxoid; clostridium perfringens type a/c, beta1 toxoid; clostridium perfringens type a/c, beta2 toxoid - clostridium - pig

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - clostridium septicum toxoid; clostridium novyi type b toxoid/cells; moxidectin; clostridium tetani toxoid; corynebacterium pseudotuberculosis exotoxin; selenium present as sodium selenate; clostridium perfringens type d toxoid; clostridium chauvoei toxoid/cells - clostridium septicum toxoid 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine; moxidectin 5 g/litre; clostridium tetani toxoid 0 vaccine; corynebacterium pseudotuberculosis exotoxin 0 vaccine; selenium present as sodium selenate 2.5 g/litre; clostridium perfringens type d toxoid 0 vaccine; clostridium chauvoei toxoid/cells 0 vaccine - ectoparasiticide

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h) - clostridium tetani toxoid antigen (formaldehyde inactivated) 5 [lf] in 0.5 ml - tenivac® is a vaccine indicated for active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older. a severe allergic reaction (e.g., anaphylaxis) after a previous dose of tenivac or any other tetanus toxoid or diphtheria toxoid-containing vaccine or any other component of this vaccine is a contraindication to administration of tenivac. [see description (11) .] because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no adequate and well-controlled studies of tenivac administration in pregnant women in the u.s. there are insufficient human data from tenivac administered during pregnancy to establish the presence or absence of a vaccine-associated risk. a developmental toxicity study has been performed in female rabbits administered a single human dose of tenivac prior to mating and during gestation. this study revealed no evidence of harm to the fetus due to tenivac. (see animal data ) data animal data in a developmental toxicity study, female rabbits received a single human dose (0.5 ml) of tenivac by intramuscular injection 17 and 10 days prior to mating, and on gestation days 6 and 29. no adverse effects on pre-weaning development up to post-natal day 35 were observed. there were no vaccine-related fetal malformations or variations observed. it is not known whether tenivac components are excreted in human milk. data are not available to assess the effect of administration of tenivac on breastfed infants or on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for tenivac and any potential adverse effects on the breastfed child from tenivac or from the underlying maternal condition. for preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine. tenivac is not approved for use in infants and children younger than 7 years of age. safety and effectiveness of tenivac in this age group have not been established. in one clinical study, (tdc01) 449 participants 65 years of age and over, including 192 participants who were 75 years of age and over received a dose of tenivac. a lower proportion of participants 65 years of age and over had a pre-vaccination seroprotective level of antibody to tetanus toxoid and diphtheria toxin compared to adolescents and adults less than 65 years of age. the proportion of participants 65 years of age and over with a seroprotective level of antibody following tenivac was marginally lower for tetanus and lower for diphtheria compared to younger participants. in general, rates of solicited adverse events were not higher in participants 65 years of age and over compared to younger participants. [see adverse reactions (6) , clinical pharmacology (12.1), and clinical studies (14.2) .]